Treatment of Erythematotelangiectatic Rosacea with Laser and Topical Beta Blocker: A Split-Face Case Study

Main Article Content

Eryn Patin
Department of Dermatology, Massachusetts General Hospital, Boston, MA; The University of Texas Southwestern Medical School, Dallas, TX

Kathyana P. Santiago Mangual
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

Sepideh Ashrafzadeh
Department of Dermatology, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA

Arianne Shadi Kourosh
Harvard Medical School, Boston, MA; Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA

Sandy Tsao
Department of Dermatology, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA

Keywords

rosacea, case report, Erythematotelangiectatic Rosacea, laser, timolol maleate, Topical Beta Blocker

Abstract

Introduction: Erythematotelangiectatic rosacea (ER) is the most common rosacea subtype, yet it is the most difficult to control with most standard topical and oral therapies.


Case Report: We present a case of a 63-year-old male with persistent facial burning, flushing, erythema, and telangiectasias, consistent with severe ER, unresponsive to a 10-year course of oral doxycycline. Following the twice-daily topical application of timolol maleate and two pulsed-dye laser (PDL) treatments over an 8-week period, both subjective and objective improvements in the patient's ER were observed.


Discussion and Conclusions: This case report illustrates timolol maleate as a potential adjuvant to PDL therapy for the management of severe ER. To our knowledge, this represents the first case of ER successfully treated with both timolol maleate and PDL, offering an additional treatment option for patients with this challenging disease.

References

1. Nguyen C, Kuceki G, Birdsall M, et al. Rosacea: Practical Guidance and Challenges for Clinical Management. Clin Cosmet Investig Dermatol. 2024;17:175-190.

2. Survey Shows Insurance Covers Rosacea Medication, But Not Laser Treatments. rosacea.org. Published July 25, 2023. https://www.rosacea.org/blog/2023/july/survey-shows-insurance-covers-rosacea-medication-but-not-laser-treatments

3. Logger JGM, Olydam JI, Driessen RJB. Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action. J Am Acad Dermatol. 2020;83(4):1088-1097.

4. Al Mokadem SM, Ibrahim AM, El Sayed AM. Efficacy of Topical Timolol 0.5% in the Treatment of Acne and Rosacea: A Multicentric Study. J Clin Aesthet Dermatol. 2020;13(3):22-27.

5. Wei D, Hamblin MR, Wen X. A randomized, controlled, split-face study of topical timolol maleate 0.5% eye drops for the treatment of erythematotelangiectatic rosacea. J Cosmet Dermatol. 2021;20(12):3968-3973.

6. Al Mokadem SM, Ibrahim AM, El Sayed AM. Efficacy of Topical Timolol 0.5% in the Treatment of Acne and Rosacea: A Multicentric Study. J Clin Aesthet Dermatol. 2020;13(3):22-27.

7. Wilkin J, Dahl M, Detmar M, et al. Standard Grading System for rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. Journal of the American Academy of Dermatology. 2004;50(6):907-912.

8. Tanghetti EA, Dover JS, Goldberg DJ, et al. Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0. J Drugs Dermatol. 2018;17(6):621-626.

9. Shi W, He H, Jiang J, Gao Y, Quan H. Timing and Efficacy of 595-nm Pulsed-Dye Laser Combined with 0.5% Timolol Maleate Solution in the Treatment of Superficial Infantile Hemangiomas. Clin Cosmet Investig Dermatol. 2021;14:1593-1599.

Article Sidebar

PDF
Published
2025-09-07
DOI: https://doi.org/10.25251/e9yxtj18

Article Details

How to Cite
1.
Treatment of Erythematotelangiectatic Rosacea with Laser and Topical Beta Blocker: A Split-Face Case Study. J of Skin. 2025;9(5):2684-2690. doi:10.25251/e9yxtj18
Issue
Vol. 9 No. 5 (2025): September 2025 Issue
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.